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Objective. This study aims to evaluate the effect of daily dietary nutritional supplement on somatic, psychological, and urogenital
symptoms in postmenopausal women. Material and Methods. In this study 28 healthy, symptomatic, peri- and postmenopausal
women of 47–67 years of age were allocated to use the nutritional supplement JuicePLUS+. Primary research parameters:
Menopause Rating Scale (MRS) was used to assess menopausal symptoms at baseline and after 8 and 16 weeks of treatment.
Secondary parameters: proliferation behaviour of vaginal smear was scored at baseline and after treatment. Results. Treatment
with the supplement resulted in a reduction of somatic, psychological, and urogenital symptoms. The overall MRS score showed
an average improvement of 44.01%. Most benefits were observed for the psychological symptoms irritability (60.55%) and physical
andmental exhaustion (49.08%); modest effects were observed for hot flashes (44.86%) and sleeping problems (35.56%).There was
a minor improvement in sexual problems; 6 women reported an increased libido. No statistically significant effect was found in
vaginal dryness and proliferation behaviour of vaginal mucosa. No adverse effects were observed. Conclusion. Dietary nutritional
supplement may constitute an effective alternative therapy to conventional alternative medicine for somatic, psychological, and
sexual symptoms.
1. Introduction
Midlife and older women are often affected with climacteric
symptoms like hot flashes, sleeping disturbance, psycholog-
ical symptoms, and vaginal dryness. Vasomotor symptoms
concern more than 50% of the menopausal women from
premenopause to peri- and postmenopause [1] and are most
strongly associated with menopausal status [2].
The Study ofWomen’s Health Across the Nation (SWAN)
from 2013 shows that the median age at the final menstrual
period was 52,5 years without any difference in ethnic
groups. Socioeconomic factors such as higher educational
level and being employed, prior oral contraceptive use, and
a better health-conscious behaviour with less alcohol and
nonsmoking were associated with later age at menopause [3].
Menopausal symptoms were also influenced by demographic
variables (education, employment status), lifestyle variables
(smoking, activity level, and BMI), and mental healthiness
[4].
Hormone supplement therapy is well established for
reversing the manifestations of low estrogen levels and can
reduce the frequency of hot flashes. A review from 2004
shows a significant reduction in the hot flash frequency for
hormone therapy compared to placebo [5]. However, studies
report side effects [5] and risks of hormone therapy, such
as cardiovascular diseases and breast cancer [6, 7]. Women
who cannot take hormones because of breast cancer or other
risks or women who want to prevent risks of a hormone
therapy search for alternative medicine for the treatment
of menopausal symptoms. More than 50% of symptomatic
German women with a mean age of 52.6 years have used
some form of alternative medicine [8]. Available, for exam-
ple, are Cimicifuga racemosa, red clover, or soy isoflavone
extracts.The results of studies are controversial. Trials do not
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support the efficacy or have mixed results for the efficacy of
isoflavones [9]. Cimicifuga provides evidence for the efficacy
in treatment of climacteric symptoms [10].
Lifestyle variables such as nonsmoking, less alcohol,
higher activity level, and lower BMI can influence meno-
pausal symptoms [4]. For a health-conscious behaviour
nutrition is of growing importance. In contrast to the desire
for well-balanced nutrition there is insufficient time for
preparing fresh fruit and vegetable. An enormous variety of
nutrition supplements suggest a benefit for the well-being,
probably also for the intensity of menopausal symptoms. We
know that nutrition with nutritional supplement is important
for many processes in the metabolism.
In this study we respond to the question of how far a
dietary supplementation of plant substances, in this case Jui-
cePLUS+ by The JuicePLUS+ Company, can reduce somatic,
psychological, and urogenital symptoms in postmenopausal
women. A publication from 2013 presented the data basis of
JuicePLUS+ available to date and reported beneficial effects
and side effects of the nutritional supplement [11]. Until now,
data on the effect of JuicePLUS+ on menopausal symptoms
have not been available.
2. Methods
2.1. Study Design and Participants. Twenty-eight women
of 47–67 years of age were recruited from the medical
office of gynecology situated in the center of Nuremberg
to participate in an open, 16-week trial without control,
designed to examine the effects of dietary supplementation of
plant substances on menopausal symptoms. All patients gave
consent to participate in the study.
Inclusion criteria were as follows: women were eligible
for the study if they were in menopausal transition or post-
menopausal, in generally good health, reporting climacteric
symptoms according to the Menopause Rating Scale (MRS),
and currently not using any type of systemic hormone
therapy or hormonal contraceptives. Exclusion criteria were
as follows: women unwilling to take daily dietary nutritional
supplement for the 16-week study period, use of other food
supplements, allergies to the constituents of the dietary
supplementation, and current severe illness like cancer.
2.2. Nutritional Supplement. To evaluate the effect of daily
dietary supplementation with plant substances, we selected
the plant concentrate JuicePLUS+ by “The JuicePLUS+ Com-
pany Europe Ltd.”
JuicePLUS+ is an encapsulated powder concentrate made
of powdered juice of 30 sorts of fruits, vegetables, and berries.
There are three different powder compositions: fruit blend,
vegetable blend, and berry blend. The preparation is entirely
natural. It is free from gluten, sugar, lactose, artificial aromas,
and colors and free from chemical stabilisers. The fructose
level is unknown. Vitamin E, ascorbic acid, folic acid, and ß-
carotene are admixed through the company to provide firm
concentrations; the additives are of natural origin [12]. The
single constituents are listed in a publication from 2013 [11].
Studies about the effect of JuicePLUS+ demonstrated
numerous positive effects on the organism. Vitamins, min-
erals, and secondary plant substances have an impact on
the immune system. JuicePLUS+ reduces the homocysteine
as a marker of oxidative stress [13–15] and increases the
blood level of antioxidants [16, 17]. A study from Smith et
al. shows an improvement of the general condition and life
quality under daily supplementation with JuicePLUS+ [18].
Another trial about the effect of JuicePLUS+ verifies a positive
influence of the plant substances on the extent of treatment
of resistant chronic periodontitis and a positive sense of well-
being [19].
2.3. Treatment and Measurements. All study participants
took the plant concentrate JuicePLUS+ in accordance with
the manufacturer’s recommendations: 2 capsules daily of the
fruit, vegetable, and berry mixture.
Prior to the start of the study, the participants had under-
gone a standardized questionnaire on demographic charac-
teristics, including age, educational level, age at menopause,
time since menopause, and use of medication.
Data were collected at baseline and after 8 and 16 weeks of
use of the nutritional supplement: In a general examination
blood pressure, weight, and height were measured and the
body mass index was calculated as weight (kg)/height (m2).
TheMenopause Rating Scale was used to evaluatemenopause
symptoms.
The MRS is composed of 11 items assessing menopause
symptoms and is divided into three subgroups [20]:
(1) Somatic symptoms: hot flashes, heart discomfort,
sleeping problems, and muscle and joint problems.
(2) Psychological symptoms: depressive mood, irritabil-
ity, anxiety, and physical and mental exhaustion.
(3) Urogenital symptoms: sexual problems, bladder
problems, and vaginal dryness.
Each item is graded by the participant, with scores from 0
to 4 (0: absent; 1: mild; 2: moderate; 3: severe; 4: very severe).
A maximal MRS score of 16 can be achieved in somatic and
psychological symptoms and 12 in urogenital symptoms.
In a gynecological examination, vaginal smear was
obtained from the vagina. The proliferation behaviour was
scored under a light microscope two times at baseline and
after 16 weeks and was classified into different categories [21].
The proliferation behaviour is an indicator for the quality
of the vaginal mucosa and indirectly for the hormonal status
and the level of dryness. Postmenopausal women usually
show a lower proliferation behaviour and are often seriously
affected by vaginal dryness.
In the absence of a placebo group in our trial, we
searched for a placebo group from a comparable study about
alternative medicine in treatment of menopausal symptoms.
We found the double-blind, placebo controlled trial from
Carmignani from2010.He compared the effects of dietary soy
supplementation, low-dose hormone therapy, and placebo
on menopausal symptoms [22]. The inclusion criteria are
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comparable to our trial. The placebo group and the hormone
therapy group consist of 20 menopausal women, between 40
and 60 years of age, who had their last menstrual period
more than 12 months previously. The study design was
equivalent to using Menopause Rating Scale to evaluate
menopausal symptoms at baseline and after 8 (visit 2) and 16
weeks (visit 3).
2.4. Statistical Analysis. In our trial some women were yet
in menopausal transition (last menstrual period dates back
to less than 12 months). For comparison with the placebo
group from [22], in which all women were postmenopausal
and without hysterectomy, we divided the participants into 2
groups:
(i) Analysis group 1: all compliant women, 𝑛 = 28.
(ii) Analysis group 2: all postmenopausal womenwithout
hysterectomy, 𝑛 = 13, in comparison with placebo
group and hormone therapy group.
Data were analyzed in both groups. Continuous data
referring to women’s epidemiological and clinical charac-
teristics were analyzed descriptively, such as age, blood
pressure, BMI, age at menopause, and age at the beginning of
symptoms. The focus was on mean and standard deviation.
The longitudinal data from Menopause Rating Scale were
analyzed using median, standard deviation, and mean, and
interquartile range (IQR) and 5th and 95th percentile were
calculated for baseline and after 8 and 16 weeks. Changes
in menopausal symptoms were addressed by absolute differ-
ences in MRS comparing visit 3 with baseline and analyzed
by the Wilcoxon signed-rank test. Comparisons to results
from the literature with respect to different treatment groups
were done by corresponding 95% confidence intervals. As the
results in [22] only show point estimates of the mean without
confidence intervals, we only conclude a tendency. If the
mean lies in the confidence interval (CI), no difference can
be shown. If the mean lies above or below the CI, we assume
a tendency at the expense or in favour of the respective group.
𝑃 values less than 0.05 were considered statistically
significant. For analyzing the data the statistical package SAS
9.4 was used.
3. Results
In total, 30 women were included in the study. Compli-
ance was high, 28 women completed 16 weeks, and only 2
women were terminated early due to relocation and were not
included in the data analysis.
Table 1 shows the baseline characteristics of the partici-
pants according to the analysis group. The following results
refer to analysis group 1 with all 28 participants. The mean
age of the women was 54.9 years (SD 5.2). Women had been
postmenopausal for a mean of 6.8 years (SD 7.7) and mean
age at menopause was 48.8 years (SD 5.4).
The beginning of the first menopause symptoms was 2.4























Boxplots to compare overall MRS scores at visits 1, 2, and 3
Figure 1: Boxplots comparing overall MRS scores at baseline and
at visits 2 and 3, analysis group 1, 𝑛 = 28. This figure reflects the
course of the overall MRS score at visits 1, 2, and 3. The box and
whisker plots include the median, the mean, the interquartile range
(IQR: defining the inner 50%of the data), the 5th and 95th percentile
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Boxplots to compare subgroups of MRS score







Figure 2: Boxplots comparing MRS subgroups at baseline and at
visits 2 and 3, analysis group 1, 𝑛 = 28. This figure reflects the course
of the subgroups of MRS score at visits 1, 2, and 3. The box and
whisker plots include the median, the mean, the interquartile range
(IQR: defining the inner 50%of the data), the 5th and 95th percentile
(upper and lower whiskers), and outlier. ⬦, mean.
25.2 kg/m2 and mean blood pressure was 126.6/78.7mmHg.
We proved no essential changes in BMI and blood pressure
until visit 3.
A statistically significant decrease in the overall baseline
MRS score and in the scores for all subscales was found after
16weeks in all groups.The overallMRS score at the beginning
was 17.86 at baseline and 10.00 at visit 3 in analysis group 1.
This means an average improvement of 44.01%.
The boxplots in Figures 1 and 2 reflect the course of the
overall MRS and the MRS score in the subgroups at baseline
and at visits 2 and 3 in analysis group 1 with all women (𝑛 =
28).
The highest MRS score at baseline was in the psycho-
logical symptoms group with 7.61 points. Intergroup analysis
revealed the best improvement in psychological symptoms
with an average of 45.07% (−3,43). The reduction of the MRS
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Table 1: Characteristics of the participants according to analysis groups 1 and 2.
Characteristics Analysis group 1, 𝑛 = 28 Analysis group 2, 𝑛 = 13
Mean age (years ± SD) 54.86 ± 5.18 55.54 ± 4.89




































Baseline total MRS (±SD)a 17.86 ± 6.16 17.54 ± 5.39
Baseline somatic symptoms, mean (±SD)a 6.82 ± 3.06 6.92 ± 3.48
Baseline psychologic symptoms, mean (±SD)a 7.61 ± 3.27 7.00 ± 2.77
Baseline urogenital symptoms, mean (±SD)a 3.43 ± 2.63 3.62 ± 2.29
𝑄1, first quartile;𝑄3, third quartile; SD, standard deviation.
aCalculated using Menopause Rating Scale.
score referring to irritability was 60.55% and physical and
mental exhaustion was 49.08%.
A modest effect with 40.32% (−2.75) was observed
for somatic symptoms. Hot flashes and sleeping problems
decreased by 44.86% and 35.56%. Minor improvement was
observed concerning urogenital symptoms; we found a
reduction of overall minus 1.68 points. Table 2 reflects the dif-
ferences in MRS score between the subgroups’ psychological,
somatic, and urogenital symptoms at visit 3 and baseline.
In the group of urogenital symptoms, sexual problems
(−0.79) improvedmost likely; 6women reported an increased
libido (21.43%). Bladder problems showed a minus of 0.5
points.
There was no statistically significant positive effect in
vaginal dryness and proliferation behaviour of vaginal
mucosa after daily supplement of the nutritional supplement.
The score in vaginal dryness improved by minus 0,39 scores.
Table 3 reflects the change in proliferation behaviour in a
contingency table. At the beginning of trial 9, 28 women were
in category 1 (Schmitt’s proliferation value of 1 and 1-2) which
means a very low hormonal level of the vaginal mucosa. Two
women were in category 2 (proliferation value of 2 and 2-3)
and 17 in category 3 (proliferation value of 3 and 3-4). Many
women stayed in their category, 6 in category 1 and 17 in
category 3 at visits 1 and 3, which means that there appeared
to be no statistically important changes for the proliferation
behaviour of vaginal mucosa.
The best improvement over time was found already after
8 weeks. The continuing daily intake of the supplement only
leads to amarginal improvement of the overall MRS score for
the last 8 weeks. No adverse effects were observed.
There was no significant difference in overall MRS score
and in subscales comparing the subgroups of all women
(𝑛 = 28) and all postmenopausal women without hysterec-
tomy (𝑛 = 13).
For comparing the effects with a placebo and a hor-
mone therapy group, we used the results from the trial of
Carmignani [22].
Table 4 reflects that the differences in the mean values of
the placebo group in all subgroups and in the overall MRS
score are contained in the corresponding 95% confidence
intervals of analysis group 2.This leads to the conclusion that
there is no statistically significant difference in the results of
both analysis groups.
There is no significant difference between the effects of the
nutritional supplement and placebo. Comparing our results
with the hormone therapy groupwe observed no significantly
better effect of systemic hormone therapy in the treatment
of psychologic and urogenital symptoms as well. In contrast,
looking at the differences in the mean values of the hormone
therapy group, there is a trend in an improved efficacy of
hormone therapy.
The supplement with JuicePLUS+ is at least obtaining
similar effects on menopausal symptoms like placebo. Jui-
cePLUS+ is an effective and reasonable alternative to other
conventional alternative medicine without side effects.
4. Discussion
This is the first trial to investigate the efficacy of daily
dietary supplementation with encapsulated powder concen-
trate made of powdered juice for improving menopausal
symptoms using Menopause Rating Scale and validating
measures of proliferation behaviour of vaginal cells. In this
trial, treatment with the concentrated nutritional supplement
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Table 2: MRS subgroups, absolute differences (visit 3 − visit 1), analysis group 1, 𝑛 = 28.
Subjects Median Mean ± SD IQR
Difference in psychological symptoms 28 −2.00 −3.43 ± 3.04 3.5
Difference in somatic symptoms 28 −2.00 −2.75 ± 3.19 3.5
Difference in urogenital symptoms 28 −1.00 −1.68 ± 2.42 2.0
Summary of differences 28 −7.00 −7.86 ± 5.45 4.5
This table reflects the differences in MRS score between the subgroups at visit 3 and baseline.
SD, standard deviation; IQR, interquartile range.





Proliferation behaviour visit 3
1 2 3 Total
Frequency
row percent
1, 1-2, 2-1a 6 3 0 9
66.67 33.33 0.00
2, 2-3, 3-2b 1 0 1 2
50.00 0.00 50.00
3, 3-4, 4-3, 4c 0 0 17 17
0.00 0.00 100.00
Total 7 3 18 28
This table shows the change in proliferation behaviour in categories. There
appeared to be no statistically important changes for the proliferation
behaviour from baseline to visit 3.
aProliferation behaviours 1, 1-2, and 2-1: parabasal calls, small intermediate
cells.
bProliferation behaviours 2, 2-3, and 3-2: small and large intermediate cells.
cProliferation behaviours 3, 3-4, 4-3, and 4: large intermediate cells, superfi-
cial cells.
a,b,cSchmitt’s proliferation value [21].
JuicePLUS+ improved overall menopausal symptoms from
baseline to 16 weeks. The highest reductions were found in
psychological symptoms irritability and physical and mental
exhaustion.Modest effectswere observed for the single symp-
toms hot flashes and sleeping problems. Minor reduction
was in urogenital symptoms. There was no significant effect
in vaginal dryness and proliferation behaviour of vaginal
mucosa.
Themean age at menopause was 48.8 years (SD 5.4).This
is similar to results of other trials [3, 23].
4.1. Somatic Symptoms. In this trial, hot flashes and sleeping
disturbances are afflicting symptoms for all women. This
is consistent with results from a trial of 2014 [8]. The
single items hot flashes and sleeping disturbances improved
significantly; a slightly minor improvement was found for
heart discomfort. In the literature, we found inconsistent
effects of other nutritional supplements. Trials about the
effects of black cohosh and isoflavones made of soy or red
clover showed positive effects on somatic symptoms [24–
26]. Despite these trials, a review from 2006 reported mixed
effects of soy extracts and no reduction of hot flashes with red
clover [9].
4.2. Psychological Symptoms. Some of the most common
and bothersomemenopausal symptoms are depressivemood,
irritability, anxiety, and physical and mental exhaustion.
A trial from 2015 showed a strong association between
menopausal symptoms and psychiatric diseases [27]. All
psychologic symptoms improved significantly in our trial,
more than somatic and urogenital symptoms. The intake of
the plant concentrate was associatedwith an increased feeling
of well-being. Comparable effects have also been described
in a recent study [19]. Similar but less positive trend was
found in the trial of Carmignani [22]. A study about black
cohosh and St. John’s wort showed a statistically significant
improvement of depressive mood [28]. Also red clover may
reduce psychologic symptoms [26].
Our finding differs from results published in the liter-
ature, in which no improvement is seen in psychological
symptoms with neither plant substances nor hormone ther-
apy [29]. A review from 2015 about the effect of hormone
therapy on depressive mood found that estrogen improved
psychological symptoms but a combined hormone therapy
has a negative effect [30]. Therefore, hormone therapy is not
indicated for treatment of psychological symptoms. For this
reason supplementation with plant concentrate might be an
alternative in the treatment of depressive mood, irritability,
anxiety, and physical and mental exhaustion.
4.3. Urogenital Symptoms. A well functioning sexuality is
fundamental for menopausal women. The Study of Women’s
HealthAcross theNation came to the result thatmostwomen,
between 42 and 52 years of age, describe sexuality as being
still important to very important for them [31]. Unfortunately
vaginal pain and dryness increase in the late menopause
and the desire for sexuality and sexual activity decreases
[32]. The cause of urogenital problems is the decrease of
estrogen following vaginal atrophy and sexual dysfunction.
The increasing prevalence of vaginal atrophy is most between
the early and late menopause [33].
Our trial reflected a modest reduction in urogenital
symptoms. Most likely, there was an improvement in sexual
problems. Some women reported increasing libido. In the
trial of Carmignani, there was no change in sexual symptoms
neither with isoflavone nor with hormone therapy [34].
Despite other studies showing evidence to the contrary
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Table 4: Comparing with placebo group and hormone therapy group.
Menopause Rating Scale Analysis group 2, 𝑛 = 13Difference in mean, 95% CI
Analysis group




Carmignani et al. 2010
Hormone therapy group
Difference in mean
Psychological symptoms −3.31, [−4.87; −1.75] −2.5 −3.4
Somatic symptoms −2.46, [−4.27; −0.65] −2.9 −5.3
Urogenital symptoms −1.62, [−2.55; −0.69] −0.7 −2.4
Overall MRS −7.38, [−9.91; −4.85] −6 −11.1
This table shows the differences in mean value in analysis group 2 from our study and in the placebo group and hormone therapy group of Carmignani et al.
[22].
CI, confidence interval.
[26, 35], in this trial vaginal dryness showed hardly any
improvement. All participants reported a modest reduction
in intensity of bladder problems under supplementation with
the nutritional supplement.
There was no statistically significant positive effect in
vaginal dryness and proliferation behaviour of vaginal
mucosa after daily supplement of nutritional supplement.
Vaginal cytology showed no improvement in quality of the
vaginal mucosa. This is opposite to the results of the trial of
Carmignani [34].
4.4. Comparing with Placebo and Hormone Therapy. One
important question to answer is how far the placebo effect
influenced the result of this trial. In addition to the positive
effects of the plant supplement generated directly, psycholog-
ical factors may have enhanced womenmotivation regarding
self-care.
In contrast to our results, the self-care in patients with
periodontitis did not improve decisively with intake of
JuicePLUS+ in the study of Wiesinger [19].
The nutritional supplement JuicePLUS+ improved psy-
chological, somatic, and urogenital symptoms in the 16 weeks
of intake. Looking at analysis group 2, treatment with the
supplement resulted in a 47.29% reduction of psychological
symptoms, in a 35.55% reduction of somatic symptoms, and
in a 44.75% reduction of urogenital symptoms. In the study
of Carmignani, treatment with placebo and hormone therapy
showed an improvement of the symptoms in approximately
the same level. Comparing to the placebo group from the trial
of Carmignani, we found no significant difference between
the results of both groups, whichmeans there is no significant
difference between the effects of placebo and JuicePLUS+ on
menopausal symptoms. But also comparedwith the hormone
therapy group, there is no better effect of hormones in the
treatment of psychologic and urogenital symptoms as well.
However, it should be also stated that hormone therapy is
more effective in relieving somatic symptoms as well as total
MRS score compared to the results obtained for JuicePLUS+.
This leads to the conclusion that JuicePLUS+ is an effective
and meaningful alternative for women with contraindication
to or adverse effects under hormone therapy and desire of
nonhormonal therapy.
Despite conflicting study results, treatment with plant
concentrate seems to be effective in improving menopausal
symptoms.
4.5. Explanation of the Results. The effects of the plant
concentrate are not exactly explored in the whole context.
In fact we know the 30 sorts of fruits, vegetables, and
berries, but the precise composition of JuicePLUS+ and the
individual constituents of the plants are not known yet.
There are to date 29 published studies on the effect of
JuicePLUS+ demonstrating numerous positive effects on the
organism. Some studies report a distinctive antioxidant and
anti-inflammatory effect [15, 16]. Samman et al. were able to
show a reduction in homocysteine as a marker of oxidative
stress after taking JuicePLUS+ [13]. Since inflammationmight
be in relationship with menopausal symptoms, this action of
the plant concentrate would be a possible route to explain
the reduction of somatic symptoms. Individual factors such
as lifestyle variables (smoking, activity level, and BMI),
poor nutritional status, and general illness might act as a
trigger of increased antioxidants, which themselves are linked
with somatic symptoms. Therefore the plant concentrate
can replenish metabolic deficiencies, reduce oxidative stress,
support the immune system, and improvemenopausal symp-
toms.
Another explanation of the increased feeling of well-
being can be the more favorable provision of nutrients. Trials
were able to show a significant reduction in the homocysteine
level. Elevated amount of homocysteine is associated with
development of depressive mood. Nutrients such as folic
acid, magnesium, or B-vitamins play an important role in
the production of neurotransmitters. A deficiency of neuro-
transmitters might result in the development of psychologic
symptoms like depressive mood [36]. Another trial about the
effect of JuicePLUS+ verifies a positive influence of the plant
substances on the extent of treatment resistance of chronic
periodontitis and a positive sense of well-being [19].
4.6. Constructive Suggestions. Some critics may question the
duration of nutritional supplement use and think it was too
short to cause a clinical response. Just like most authors,
we observed the most significant effect on the improvement
of menopausal symptoms within the initial 8-week period
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of supplement intake. Therefore the period of 16 weeks
was satisfactory to induce effects on menopausal symptoms
[1, 37].
A possible limitation of this study is the small number of
participants. Further studies with larger number of patients
should be undertaken concerning the effect of JuicePLUS+
in the extent of climacteric symptoms.
5. Conclusion
This study shows that daily dietary supplementation with
plant substances may constitute an effective alternative ther-
apy to conventional alternativemedicine for treatment of psy-
chological symptoms and the somatic symptoms hot flashes
and sleeping disturbances. It is not able to improve vaginal
dryness and proliferation behaviour of vaginal mucosa. Since
many women with climacteric symptoms choose not to
undergo hormone therapy, the effect of JuicePLUS+ may be
useful to them.
We used the nutritional supplement JuicePLUS+ for
achieving a comparable intake of herbal substances in the
study. Herbal medicine should not be confused with dietary
supplements. Herbal medicine involves the use of plants for
medical therapeutic purposes. We know the active ingre-
dients and individual chemicals from most medical plants
and understand how they work in the body. In contrast
to that, there is a need for further studies to make clear
what ingredients are responsible for the observed effects of
JuicePLUS+.
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